Advertisement
Advertisement
U.S. Markets open in 7 hrs 55 mins
Advertisement
Advertisement
Advertisement
Advertisement

Aequus Pharmaceuticals Inc. (AQSZF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.04350.0000 (0.00%)
At close: 10:37AM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • b
    brwolf
    YAY!!!! Rooty is back LMAO!!!
  • G
    Greg
    current market cap around 10million, SCOPE should bring in around 10million per year, imed bringing in around 20 mill per year in Canada and they are very comparable companies. Once they get their products rolling, aqs going to be making big money. They just need to survive a couple more quarters then will start seeing positive cash flow
  • R
    Rootbound43
    Woof!!!
  • O
    Oscar
    I suppose traders don’t know which way the stock price will break. No one seems to be trading. The last news was pretty good but revenue generation may take awhile. Is it worth the wait???
  • O
    Oscar
    Seems like there’s a price disconnect between the Canadian side and the US side. Canadian side .075 Canadian. Or have they just not updated yet?
  • M
    MFO
    New products means new revenues , so it s certainly good news. What revenues will they generate from this deal would surely be interesting to know ?
    Bullish
  • O
    Oscar
    Ok who bought 100 shares? Are you trying to make us feel good? It’s going to take a lot more than that to make longs happy.
  • O
    Oscar
    Ok that was pretty good news in yesterday’s PR. Let’s see if Mr. Jansen can turn this into a cash machine. “Show me the Money”.
  • O
    Oscar
    The wait continues. So much for an update by Jansen. I did write the company a couple of days ago and to my surprise…. No response.
  • O
    Oscar
    I’m not sure why this can be traded on the US side and not the Canadian side. Does someone know something about this issue?
  • d
    djchill
    Not surprised from the poor financial results.

    1. Vistitan has a limited market. It will never be first line, maybe second line with a small % of MD's. it's old technology! Like Blackberry it had dominant share, used by prominent individuals...Obama. Who would buy a Blackberry now, who would invest In a Blackberry 2.0 startup.

    2. The Dry eye market is very competitive with little differentiation. How can you compete?....not with another HA product. Alcon, Allegan, J&J, Bayer, Candorvision, IMed have the market. Who ever thought they could dislodge, replace these competitors?

    3. Zepto, what a disaster.

    4. Other new products?

    I'm out!
  • b
    brwolf
    If there is a bright side I just checked current locations for Evolve and it has jumped from about 65 to the current 98 over the last couple of months. So we do have a little traction on that front and hopefully sales will start to reflect that increase. GLTA
  • O
    Oscar
    Anyone planning in attending the quarterly meeting?
  • d
    djchill
    More dry eye products!? good luck cuz that's all got.
  • M
    MFO
    All this accounting / auditing delay should be resolved for end of May .
    Let’s hope the future will be bright . CEO surely believes so as he invested his own money on this company .
  • W
    Wil
    AQSZF
    0.00%
    Aequus Pharmaceuticals
    Mon, June 13, 2022, 7:00 AM
    In this article:

    AQSZF
    0.00%

    Aequus Pharmaceuticals
    Aequus Pharmaceuticals
    VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that further to its news release on May 6, 2022 and May 26, 2022, the filing of its audited annual financial statements for the fiscal year ended December 31, 2021 and the related management’s discussion and analysis (collectively, the “Annual Disclosure”) as well at the financial statements for the three months ended March 31, 2022 and the related management’s discussion and analysis (collectively, the “Quarterly Disclosure”) continues to be delayed.

    Doug Janzen, CEO and Director commented that “Aequus provided all required information, under its control, to its auditors well before the filing deadline. However, the auditors had a number of additional questions for our primary commercial partner – which is a global business with sophisticated commercial operations, and while they have provided information to the auditor to the best of their ability, the process has taken more time than expected. This delay is not related to the Company’s internal accounting policies or procedures. We expect to be able to publicly file the reports soon after our auditor has completed their work so that the Cease Trade Order can then be lifted. Much progress has been made and we are grateful to Sandoz for their continued co-operation.”

    The Company expects to file the Annual Disclosure concurrently with the Quarterly Disclosure soon after the requested information is in hand and intends to provide updates on further developments in respect of this matter promptly following their occurrence. We hope to issue another update later this coming week.
  • O
    Oscar
    I don’t like this unreported quarter. How could the books be that far off? They can’t get a report out a few days after it’s required? I’ll be shocked if there’s good news in the report.
  • r
    rahul_456r
    What’s wrong with this share ?
    Will it go up or down ?
  • a
    andre
    I would like to summarize and furthermore add some more information to the news of last week.

    This is by now the news with the biggest impact on the business of AQS.

    British Columbia decided to replace the existing product with Sandoz Tacrolismus. We talk about approx. 5.000 patients and additional 300 to 400 new patients every year, needing Sandoz Tacrolismus on a daily basis. We talk about a business worth up to 20 Mio CADs for the current product.

    And the best is: The impact on the revenue startet already end of last year and will rapidly grow this quarter, as all patients should have Sandoz Tacrolismus end of March latest.

    AQS will not generate 20 Mio CADs per year, as:

    - they will not get the whole revenue, Sandoz will have of course a part of it.
    - Sandoz is cheaper than the current product
    - Tacro IR patients will not (yet) be provided with Sandoz Tacro

    Anyway: Due to this deal, AQS will generate several millions CAD revenue year over year, without having additional sales cost.

    Therefore, we could be near to break even in a few quarters.

    And we have to see, if there is a need at all to raise new money, as revenue will grow rapidly from January on.

    This is the current situation without! the Evolve opportunity in Canada and later in in the US.

    It will be interesting to see, when the market starts to understand the complete new situation of AQS.
    Bullish
Advertisement
Advertisement